COMP <GO>
SLDB vs ATTO // RSI-14 & 200D SMA MOMENTUM
Solid Biosciences Inc. (NASDAQ) VS. Attovia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SLDB 0
— ATTO 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ATTO
LAST: $6.39 (-1.39%) • MKT CAP: $685.2M
rsi-technicals
42.4
LAST: $15.27 (-3.35%) • MKT CAP: $697.1M
rsi-technicals
43.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLDB VS. ATTO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SLDB | ATTO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -22.98% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 42.4 | 43.4 | -1.03 | ATTO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $685.2M | $697.1M | -$11.9M | ATTO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SLDB REV | ATTO REV | SLDB GROSS % | ATTO GROSS % | SLDB FCF | ATTO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$157.4M | — |
| FY 2024 | $0 | — | — | — | -$100.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLDB // BETA —
ATTO // BETA —